ATLANTA--(BUSINESS WIRE)--Sept. 19, 2006---Sciele Pharma, Inc. (NASDAQ:SCRX), a specialty pharmaceutical company, today announced that it has entered into an agreement for a new $100 million credit facility for a five-year term, which replaces the Company’s current $20 million credit facility. The new credit facility was underwritten by a syndicate of financial institutions led by UBS Investment Bank and LaSalle Bank National Association.
